Showing results (171-180 of 197) with videos related to
Sort By:
Pageof 20
JAMA Dermatology|October 17, 2012
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoidesStuart R Lessin, Madeleine Duvic, Joan Guitart, et al.Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.Journal of the American Academy of Dermatology|April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsAlan Menter, Alice Gottlieb, Steven R Feldman, et al.Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.Journal of the American Academy of Dermatology|April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologicsAlice Gottlieb, Neil J Korman, Kenneth B Gordon, et al.Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.Journal of the American Academy of Dermatology|May 22, 2016
Clinical meaningfulness of complete skin clearance in psoriasisBruce Strober, Kim A Papp, Mark Lebwohl, et al.Pageof 20